First-in-Class Sjogren's Drug Passes Mid-Stage Test

(MedPage Today) -- MILAN -- An investigational protein drug called dazodalibep with broad-spectrum activity against autoimmune pathways reduced symptoms of Sjögren's syndrome in a two-stage, phase II randomized trial with a unique design...

Source: MedPage Today Rheumatology - June 3, 2023 Category: Rheumatology Source Type: news